China’s Emerging Global Vaccine Footprint
While demand for COVID-19 vaccines may be decreasing, the pandemic highlighted the long-term importance of boosting local vaccine manufacturing in developing countries. China’s role as a key vaccine donor and provider during the pandemic has positioned it to support this new agenda, making it a critical emerging player in the global vaccine manufacturing landscape. As a mission-driven consultancy looking to encourage China’s engagement in global health, Bridge Consulting aims to identify and drive China’s involvement in this important endeavor.
Article Series: Towards Africa's Local Vaccine Manufacturing
Latest News
Pandemic Preparedness
Joint Vaccine Production
Everest Medicines ends mRNA deal with Providence Therapeutics, terminating the rights to the licensing out of their joint mRNA COVID-19 vaccine candidate. Despite the termination of the agreement and subsequent $4 million fee, they will still retain full rights to all intellectual property rights provided, transferred, or made available by Providence prior to the termination, and be able to continue developing self-discovered products utilizing the mRNA platform — Pharmaceutical Technology